Patients with type 2 diabetes treated with metformin and the GLP-1R agonist exenatide for 1 year display significantly reduced circulating TG, apoB48, and FFA following an early meal (50 g of fat, 75 g of carbohydrates, 35 g of protein). Here, GLP1R is linked to type 2 diabetes mellitus.